Aurinia Pharmaceuticals (AUPH) Research & Development (2020 - 2026)
Aurinia Pharmaceuticals' (AUPH) quarterly Research & Development came in at $7.5 million in Q1 2026, up 30.07% YoY from $5.7 million in Q1 2025, and down 31.44% on a QoQ basis from $10.9 million in Q4 2025.
Aurinia Pharmaceuticals (AUPH) Research & Development (2020 - 2026) Analysis & Trends
Aurinia Pharmaceuticals (AUPH) has 7 years of Research & Development data on file, last reported at $7.5 million in Q1 2026.
- Quarterly Research & Development rose 30.07% year-over-year to $7.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $34.2 million (up 63.19% YoY) and the FY2025 annual result came in at $32.5 million, up 56.39% from the prior year.
- Research & Development declined to $7.5 million in Q1 2026, from $10.9 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $13.6 million in Q3 2023 to a low of $3.0 million in Q3 2024.
- A 5-year average of $8.6 million and a median of $8.4 million in 2025 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2023 — Research & Development surged 228.95% — and 2024, when it slumped 77.6%.
- Tracing AUPH's Research & Development over 5 years: stood at $9.9 million in 2022, then gained by 3.63% to $10.2 million in 2023, then dropped by 20.74% to $8.1 million in 2024, then jumped by 34.39% to $10.9 million in 2025, then slumped by 31.44% to $7.5 million in 2026.
- The last three Research & Development figures came in at $7.5 million (Q1 2026), $10.9 million (Q4 2025), and $8.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Aurinia Pharmaceuticals | 2.06 Bn | 1.61 Bn | 76.67 Mn | 13.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.05 Mn |
| Mar 31, 2026 | 7.47 Mn |
| Dec 31, 2025 | 10.90 Mn |
| Sep 30, 2025 | 8.44 Mn |
| Jun 30, 2025 | 7.43 Mn |
| Mar 31, 2025 | 5.74 Mn |
| Dec 31, 2024 | 8.11 Mn |
| Sep 30, 2024 | 3.05 Mn |
| Jun 30, 2024 | 4.08 Mn |
| Mar 31, 2024 | 5.55 Mn |
| Dec 31, 2023 | 10.23 Mn |
| Sep 30, 2023 | 13.61 Mn |
| Jun 30, 2023 | 12.65 Mn |
| Mar 31, 2023 | 13.16 Mn |
| Dec 31, 2022 | 9.87 Mn |
| Sep 30, 2022 | 10.97 Mn |
| Jun 30, 2022 | 11.53 Mn |
| Mar 31, 2022 | 4.00 Mn |
| Dec 31, 2021 | 11.15 Mn |
| Sep 30, 2021 | 20.07 Mn |